GOLGA6L17P

Across TCGA pan-cancer cohorts, GOLGA6L17P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GOLGA6L17P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where GOLGA6L17P RNA is repressed in tumor relative to normal tissue. In most cancer types GOLGA6L17P is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

BRCA, COAD, and KICH are the cancer types where GOLGA6L17P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GOLGA6L17P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−0.048	<.001	6	view →
COAD	All	II,III,IV	+0.092	.022	4	view →
KICH	All	II,III,IV	+0.064	.025	1	view →
LUSC	All	All	+0.038	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GOLGA6L17P–BRCA

Open the BRCA breakdown →